BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32103493)

  • 1. Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
    Österroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Möllgård L; Derolf ÅR; Uggla B; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
    Br J Haematol; 2020 Apr; 189(1):e13-e16. PubMed ID: 32103493
    [No Abstract]   [Full Text] [Related]  

  • 2. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I treat older patients with acute myeloid leukemia.
    Arellano M; Carlisle JW
    Cancer; 2018 Jun; 124(12):2472-2483. PubMed ID: 29809277
    [No Abstract]   [Full Text] [Related]  

  • 5. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
    Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
    Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
    Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
    BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax with decitabine or azacitidine for AML.
    Das M
    Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
    [No Abstract]   [Full Text] [Related]  

  • 8. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
    Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
    Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia.
    Ramakrishnan R; Munir F; Quesada AE; Hitzler J; Cuglievan B
    Pediatr Blood Cancer; 2024 Jun; 71(6):e30974. PubMed ID: 38523255
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
    Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia.
    Brandwein JM; Hallett D; Karkhaneh M; Zhu N; Liew E; Bolster L; Hamilton M; Patterson J; Taparia M; Wu C; Van Slyke T; Bankar A; Saini L
    Am J Hematol; 2021 Jan; 96(1):E17-E20. PubMed ID: 33021743
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
    Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
    Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
    BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival.
    Jeurkar C; Wilde L; Leiby BE; Banks J; Kasner M; Keiffer G; Filicko-O'Hara J; Palmisiano N
    Leuk Res; 2021 Apr; 103():106533. PubMed ID: 33621825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
    Lao Z; Yiu R; Wong GC; Ho A
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):54-61. PubMed ID: 25545192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia.
    Lim MJ; Agha A; Im A; Raptis A; Hou JZ; Boyiadzis M; Sehgal AR; Redner RL; Dorritie K; Marks SS; Agha ME; Lim SH
    Hematol Oncol; 2018 Apr; 36(2):495-497. PubMed ID: 28664979
    [No Abstract]   [Full Text] [Related]  

  • 18. D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
    Zheng R; Xie B; Wang C; Yu B; Xu J; Tan H
    Ann Hematol; 2016 Jan; 95(1):157-159. PubMed ID: 26382274
    [No Abstract]   [Full Text] [Related]  

  • 19. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
    Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
    [No Abstract]   [Full Text] [Related]  

  • 20. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
    Huang J; Hong M; Zhu Y; Zhao H; Zhang X; Wu Y; Lian Y; Zhao X; Li J; Qian S
    Leuk Lymphoma; 2018 Nov; 59(11):2570-2579. PubMed ID: 29616840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.